skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Boron neutron capture therapy of ocular melanoma and intracranial glioma using p-boronophenylalanine

Conference ·
OSTI ID:5643007
; ; ; ;  [1];  [2]
  1. Brookhaven National Lab., Upton, NY (USA)
  2. North Shore Univ. Hospital, Manhasset, NY (USA). Div. of Ophthalmology

During conventional radiotherapy, the dose that can be delivered to the tumor is limited by the tolerance of the surrounding normal tissue within the treatment volume. Boron Neutron Capture Therapy (BNCT) represents a promising modality for selective tumor irradiation. The key to effective BNCT is selective localization of {sup 10}B in the tumor. We have shown that the synthetic amino acid p-boronophenylalanine (BPA) will selectively deliver boron to melanomas and other tumors such as gliosarcomas and mammary carcinomas. Systemically delivered BPA may have general utility as a boron delivery agent for BNCT. In this paper, BNCT with BPA is used in treatment of experimentally induced gliosarcoma in rats and nonpigmented melanoma in rabbits. The tissue distribution of boron is described, as is response to the BNCT. 6 refs., 4 figs., 1 tab.

Research Organization:
Brookhaven National Lab., Upton, NY (USA)
Sponsoring Organization:
USDOE; USDOE, Washington, DC (USA)
DOE Contract Number:
AC02-76CH00016
OSTI ID:
5643007
Report Number(s):
BNL-46148; CONF-901226-4; ON: DE91013808
Resource Relation:
Conference: 4. international symposium on neutron capture therapy, Sydney (Australia), 3-7 Dec 1990
Country of Publication:
United States
Language:
English